Results 101 to 110 of about 25,067 (205)

Lynparza (olaparib)

, 2016
Pred kratkim je bilo v EU registrirano novo tarčno zdravilo LynparzaTM (olaparib) za zdravljenje bolnic z recidivnim seroznim karcinomom jajčnikov, jajcevodov ali primarnim peritonealnim seroznim karcinomom (PPSC), ki imajo znano mutacijo v genih BRCA1/2
Erik Škof, Mateja Krajc
core  

NLRP4 drives olaparib resistance in pancreatic cancer

Olaparib has been approved as a treatment for metastatic pancreatic ductal adenocarcinoma in patients with BRCA1 (BRCA1 DNA repair associated) or BRCA2 mutations.
Xianjun Yu, Si Shi, Mingming Xiao
core   +1 more source

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer

, 2017
Women with platinum resistant ovarian cancer (OC) have limited responses to standard therapy, and clinical trials with novel agents are therefore highly justified.
R. Roux, Nicum, S, Strauss, VY, Roberts, C, Strauss, Victoria Y., McGregor, NS, Hall, M, Michael, A, S. Nicum, McGregor, Naomi S., Roux, R, Nicum, Shibani, Roberts, Corran, A. Michael, McNeish, I, N. McGregor, V.Y. Strauss, I. McNeish, M. Hall, C. Roberts   +19 more
core   +1 more source

Treatment outcomes of patients with BRCA-mutated, recurrent ovarian cancer in University Hospital Center Split

Libri Oncologici, 2022
Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer treated at the University Hospital Center Split in the period from June 2016 to ...
Branka Petrić-Miše, Mirko Pešo, Darijo Hrepić, Vesna Telesmanić-Dobrić, Eduard Vrdoljak   +4 more
doaj  

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

PARP inhibitor combinations with Olaparib for synergistic efficacy in Olaparib-resistant triple-negative breast cancer cells [PDF]

, 2023
Triple-negative breast cancer (TNBC) is associated with aggressive and heterogenous tumour phenotype, early tumour relapse and poor prognosis than other types of invasive breast cancer.
Yusoh, Nur Aininie
core  

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, Volume 16, Issue 7, Page 1370-1386, July 2026.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization [PDF]

, 2017
PURPOSE: Maintenance therapy with olaparib has improved progression-free survival in women with high-grade serous ovarian cancer (HGSOC), particularly those harboring BRCA1/2 mutations.
Bowtell, D, Julia V. Burnier, Stephanie Lheureux, Jane D. Robertson, Karakasis, Katherine, Ho, Tony W, Lheureux, S, Ledermann, J, Gilks, CB, Ho, TW, Kirsten M. Timms, Oza, Amit M, Gourley, C, Kohn, Elise C, J. Carl Barrett, Lheureux, Stephanie, Hodgson, DR, David Bowtell, Robertson, JD, Burnier, JV, Elise C. Kohn, Barrett, J. Carl, Bowtell, David D.l., Timms, KM, Panzarella, Tony, Kaye, Stanley B., Runswick, Sarah, Scott, C, Karakasis, K, Gourley, Charlie, Scott, Clare L, Timms, Kirsten M, Lai, Z, Lanchbury, Jerry S, Runswick, S, Kaye, S, Jonathan Ledermann, Panzarella, T, O'connor, Mark J, Robertson, Jane D, Ledermann, Jonathan, Zhongwu Lai, Amit M. Oza, Lanchbury, JS, Claire Scott, Brian A. Dougherty, Gilks, Blake, Barrett, JC, Ursula Matulonis, Jerry S. Lanchbury, Stan Kaye, Tony W. Ho, Matulonis, U, Burnier, Julia V, Matulonis, Ursula A, Dougherty, Brian A, Dougherty, BA, Oza, AM, Darren R. Hodgson, Katherine Karakasis, Lai, Zhongwu, Hodgson, Darren, Sarah Runswick, O'Connor, MJ, Kohn, EC, C. Blake Gilks, Tony Panzarella, Charlie Gourley, Mark J. O'Connor   +68 more
core   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability

Genes, Chromosomes and Cancer, Volume 65, Issue 7, July 2026.
ABSTRACT PKMYT1 has emerged as a promising therapeutic target distinguished by its tumor‐selective expression and essential role in replication stress management. Unlike WEE1, PKMYT1 is dispensable in normal cell cycles but critical for cancer cells coping with DNA damage, establishing a broad therapeutic window.
Lingxi Li, Binfan He, Mengmeng Hao, Ye Liu, Shunxin Song, Rongzhang He   +5 more
wiley   +1 more source